Loading asset research
Abeona Therapeutics Inc. Common Stock
ABEONasdaq · USD · StocksQuote as of · Exchange session not verified$5.41
-1.28%
Today
ABEO
Loading 1D prices…
Market cap
$309.7M
Volume
1.6M
52w high
$7.6552w low
$4.00Company profile
Abeona Therapeutics Inc. Common Stock
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Cleveland, OH, United States
Employees
226
Fiscal year end
1231
CIK
318306
Session & valuation
Open$5.55
Previous close$5.48
Day high$5.66
Day low$5.40
30-day avg. volume1.5M
Outstanding shares57.2M
Diluted EPS$1.01
Latest annual period
P/E (trailing)5.36
P/E (forward)-29.01
Price / book2.42
Beta1.32
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| IFRXInflaRx N.V. Common Stock | $308M | — | — | -$0.68 | +1.95% | Buy |
| VNDAVanda Pharmaceuticals Inc. Common Stock | $307.8M | $216.1M | -102.03% | -$3.74 | +0.99% | Buy |
| UPBUpstream Bio Inc. Common Stock | $313.8M | $2.9M | -5026.03% | -$2.66 | -0.35% | Buy |
| VCREVicore Pharma Holding AB American Depositary Shares | $303.5M | — | — | -$19.90 | -6.34% | Unrated |
| EBSEmergent BioSolutions Inc. Common Stock | $319.4M | $742.9M | +7.08% | $0.93 | +5.96% | Hold |